FDA Approves First Oral Antiviral Drug to Treat COVID-19 in Adults
U.S. Food and Drug Administration
Paxlovid reduced the proportion of people with COVID-19-related hospitalization or death by 86 percent
Paxlovid reduced the proportion of people with COVID-19-related hospitalization or death by 86 percent
Unvaccinated individuals may receive a single dose of a bivalent vaccine, not multiple doses of the monovalent mRNA vaccines